Table 1

Information that will be extracted from each included study

Study design and methodsCitation information (authors, journal, year of publication, volume, issue and page numbers); study design (randomised trial, non-randomised trial, case-control study, cohort study); study location (city, country) and period of study (start and end date, ie month and year).
Methods for generating randomisation sequence, concealing allocation of interventions and blinding of outcome assessment; number of participants randomised and number with complete outcome data for each outcome; names of outcomes announced in study protocol but not reported in study publication, and other biases.
Participant characteristicsAge, sex, study location, study inclusion and exclusion criteria, flow of numbers of participants during the study (from participant enrolment to completion of data collection).
InterventionDefinition of fractional dose, manufacturer of vaccine, immunisation schedule (frequency, timing, interval between doses, etc), OPV co-administration, route of administration (intradermal, sub-cutaneous, etc) and types of devices used for administration of the fractional doses (name, manufacturing company, etc).
ComparisonDefinition of full dose, manufacturer of vaccine, immunisation schedule (frequency, timing, interval between doses, etc), OPV co-administration and route of administration (intramuscular, sub-cutaneous, etc).
Outcome measuresOutcomes reported in the study (immunogenicity, adverse events following polio vaccination, vaccine-associated paralytic polio, wild poliovirus-associated paralytic polio, mucosal immunity), how they were defined and how they were measured.
Outcome dataSeroconversion (number of participants randomised and number who seroconverted in each arm), antibody titres (geometric mean plus SD or median and range in each arm), number of participants randomised and number who experienced the following events in each arm: adverse events following IPV vaccination, vaccine associated paralytic polio, wild poliovirus-associated paralytic polio, mucosal immunity.